All In Biotech

Drug Trial Radar · NCT02612454

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 Months to <18 Years of Age With Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

880

Actual

Start

Oct 15, 2015

Primary completion

Oct 9, 2026

Study completion Oct 9, 2026

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Sanofi
First posted
Nov 23, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD. The secondary objectives of the study are: * To assess the long-term efficacy of dupilumab in pediatric participants with AD * To assess the trough concentrations of functional dupilumab in serum and the immunogenicity in pediatric participants with AD after re-treatment with dupilumab Optional Pre-filled Pen (PFP) Sub-Study in pediatric patients ≥2 to \<12 years of age with AD Co-Primary Objectives are: * To evaluate the pharmacokinetic (PK) of dupilumab PFPs * To evaluate the safety of dupilumab PFPs Secondary Objective is: \- To evaluate the immunogenicity of dupilumab PFPs

Conditions

  • Atopic Dermatitis

Interventions

  • DupilumabDrug

    Weight-tiered dosing administered subcutaneous (SC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of treatment-emergent adverse events (TEAEs) per participant year from baseline through the last study visitTime frame: Baseline up to week 272
  2. Number of participants with at least one TEAE per participant year from baseline through the last study visitTime frame: Baseline up to week 272
  3. OPTIONAL SUB-STUDY: Pharmacokinetic (PK) of dupilumab: Peak concentration (Cmax)Time frame: Up to week 16
  4. OPTIONAL SUB-STUDY: PK of dupilumab: Trough concentration (Ctrough)Time frame: Up to week 16
  5. OPTIONAL SUB-STUDY: Incidence of TEAEs during the 12-week PFP treatment period and during entire sub-studyTime frame: Up to week 16
  6. OPTIONAL SUB-STUDY: Incidence of SAEs during the 12-week PFP treatment period and during entire sub-studyTime frame: Up to week 16

Locations

84 sites in 7 countries. Site status is shown where the registry gives one.

  • Regeneron Investigational Site

    Birmingham, Alabama

  • Regeneron Investigational Site

    Gilbert, Arizona

  • Regeneron Investigational Site

    Bakersfield, California

  • Regeneron Investigational Site

    Long Beach, California

  • Regeneron Investigational Site

    Los Angeles, California

  • Regeneron Investigational site

    Mission Viejo, California

  • Regeneron Investigational Site

    Orange, California

  • Regeneron Investigational Site

    Palo Alto, California

  • Regeneron Investigational Site

    Rolling Hills Estates, California

  • Regeneron Investigational Site

    San Diego, California

  • Regeneron Investigational Site

    Centennial, Colorado

  • Regeneron Investigational Site

    Washington D.C., District of Columbia

  • Regeneron Investigational Site

    Coral Gables, Florida

  • Regeneron Investigational Site

    Tampa, Florida

  • Regeneron Investigational Site

    Tampa, Florida

  • Regeneron Investigational Site

    Columbus, Georgia

  • Regeneron Investigational Site

    Macon, Georgia

  • Regeneron Investigational Site

    Sandy Springs, Georgia

  • Regeneron Investigational Site

    Chicago, Illinois

  • Regeneron Investigational Site

    Skokie, Illinois

  • Regeneron Investigational site

    Plainfield, Indiana

  • Regeneron Investigational Site

    Rockville, Maryland

  • Regeneron Investigational Site

    Boston, Massachusetts

  • Regeneron Investigational Site

    Boston, Massachusetts

  • Regeneron Investigational Site

    Ypsilanti, Michigan

  • Regeneron Investigational Site

    Plymouth, Minnesota

  • Regeneron Investigational Site

    St Louis, Missouri

  • Regeneron Investigational Site

    Forest Hills, New York

  • Regeneron Investigational Site

    New York, New York

  • Regeneron Investigational Site

    Rochester, New York

  • Regeneron Investigational Site

    Gahanna, Ohio

  • Regeneron Investigational Site

    Portland, Oregon

  • Regeneron Investigational site

    Philadelphia, Pennsylvania

  • Regeneron Investigational Site

    Charleston, South Carolina

  • Regeneron Investigational Site

    North Charleston, South Carolina

  • Regeneron Investigational Site

    Bellaire, Texas

  • Regeneron Investigational Site

    Fort Worth, Texas

  • Regeneron Investigational Site

    San Antonio, Texas

  • Regeneron Investigational Site

    Norfolk, Virginia

  • Regeneron Investigational Site

    Seattle, Washington

Showing 40 of 84 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.